Literature DB >> 421230

Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis.

G A Frick, R Ballentine, C W Driever, W G Kramer.   

Abstract

The effect of hydration and mannitol diuresis on the nephrotoxicity and renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) was examined in seven men undergoing treatment for testicular or bladder carcinoma. The elimination half-life averaged 26.8 hours, shorter than values previously reported from studies not employing hydration and diuresis. In addition, no signs of nephrotoxicity were observed. The results suggest that hydration and mannitol diuresis decrease the nephrotoxicity of cis-dichlorodiammineplatinum(II) by increasing its rate of elimination.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 421230

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  16 in total

1.  Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis.

Authors:  Aghilès Hamroun; Rémi Lenain; Jean Joel Bigna; Elodie Speyer; Linh Bui; Paul Chamley; Nicolas Pottier; Christelle Cauffiez; Edmone Dewaeles; Xavier Dhalluin; Arnaud Scherpereel; Marc Hazzan; Mehdi Maanaoui; François Glowacki
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

2.  Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.

Authors:  Emiko Sakaida; Shunichiro Iwasawa; Ryota Kurimoto; Takahiro Ebata; Chiaki Imai; Tomoko Oku; Ikuo Sekine; Yuji Tada; Koichiro Tatsumi; Yuichi Takiguchi
Journal:  Jpn J Clin Oncol       Date:  2016-01-10       Impact factor: 3.019

4.  Acute and long-term nephrotoxicity of cis-platinum in man.

Authors:  S Groth; H Nielsen; J B Sørensen; A B Christensen; A G Pedersen; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.

Authors:  Keizo Fukushima; Akira Okada; Hiroyuki Oe; Mika Hirasaki; Mami Hamori; Asako Nishimura; Nobuhito Shibata; Nobuyuki Sugioka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

6.  [Pharmacokinetic of platin in plasma and urine of man under 1-, 8-, and 24 h-infusion with cis-dichlorodiamine-platin (II) (cis-DDP) (author's transl)].

Authors:  H W von Heyden; H Henkel; G A Nagel; N Weinstock
Journal:  Klin Wochenschr       Date:  1982-03-01

Review 7.  A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.

Authors:  Daniel J Crona; Aimee Faso; Tomohiro F Nishijima; Kathleen A McGraw; Matthew D Galsky; Matthew I Milowsky
Journal:  Oncologist       Date:  2017-04-24

8.  Cisplatin disposition in children and adolescents with cancer.

Authors:  W R Crom; W E Evans; C B Pratt; N Senzer; M Denison; A A Green; F A Hayes; G C Yee
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

10.  Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer.

Authors:  Keiko Muraki; Ryo Koyama; Yuichiro Honma; Shigehiro Yagishita; Takehito Shukuya; Rina Ohashi; Fumiyuki Takahashi; Kenji Kido; Shin-Ichiro Iwakami; Shinichi Sasaki; Akihiko Iwase; Kazuhisa Takahashi
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.